Agilent to Buy Biocare Medical for $950M, Seeks EPS Accretion in 12 Months
Agilent Technologies will acquire Biocare Medical for $950 million, closing by its fourth fiscal quarter of 2026 and integrating into its Life Sciences and Diagnostics unit. Agilent expects the deal to boost revenue growth, be accretive to EPS in about 12 months and is backed by $1.76 billion cash.
1. Acquisition Details
Agilent Technologies agreed to acquire Biocare Medical for approximately $950 million, with the transaction expected to close by its fourth fiscal quarter of 2026, subject to customary closing conditions and regulatory approvals.
2. Strategic Rationale and Synergies
Biocare Medical specializes in immunohistochemistry and hybridization solutions, offering over 300 specialized antibodies and strong R&D capabilities. Agilent anticipates these assets will enhance its IHC offerings and expand its presence in clinical and research pathology labs.
3. Financial Impact and Timeline
The acquisition is projected to boost Agilent’s revenue growth, improve margins and be accretive to EPS roughly 12 months after closing. As of January 31, 2026, Agilent held $1.76 billion in cash and cash equivalents to support the deal.
4. Integration and Market Outlook
Biocare will integrate into Agilent’s Life Sciences and Diagnostics Markets Group, aiming to leverage cross-selling opportunities and drive non-instrument revenue. Investors are watching for momentum shifts as Agilent broadens its diagnostic portfolio with the new assets.